AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 203 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $503,000 | -69.1% | 9,400 | -72.4% | 0.05% | -81.1% |
| Q4 2019 | $1,628,000 | +10.7% | 34,100 | -24.9% | 0.24% | -4.3% |
| Q3 2019 | $1,471,000 | -63.1% | 45,400 | -43.2% | 0.25% | -46.8% |
| Q2 2019 | $3,990,000 | -1.4% | 80,000 | +33.3% | 0.48% | -2.1% |
| Q1 2019 | $4,046,000 | -6.7% | 60,000 | +6.7% | 0.49% | +5.9% |
| Q3 2018 | $4,335,000 | +58.6% | 56,207 | +17.6% | 0.46% | +34.9% |
| Q4 2017 | $2,733,000 | -14.4% | 47,799 | 0.0% | 0.34% | -17.0% |
| Q3 2017 | $3,191,000 | -49.8% | 47,799 | -61.3% | 0.41% | -40.9% |
| Q2 2017 | $6,359,000 | +112.7% | 123,599 | +141.4% | 0.70% | +99.1% |
| Q1 2017 | $2,990,000 | +30.5% | 51,200 | -6.7% | 0.35% | +37.4% |
| Q4 2016 | $2,291,000 | -17.7% | 54,900 | +4.2% | 0.25% | -7.0% |
| Q3 2016 | $2,784,000 | +84.1% | 52,700 | +46.0% | 0.27% | +75.0% |
| Q2 2016 | $1,512,000 | – | 36,100 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
| Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
| Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
| ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
| Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
| ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
| Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |